Arslon Inc. is a medical AI company developing AI-powered solutions for cardiovascular health management and early screening of coronary artery disease (CAD). Arslon’s proprietary technology analyzes standard 12-lead electrocardiogram (ECG) data using deep learning and Graph Neural Network (GNN)-based approaches to identify cardiovascular risk signals from a routine 10-second ECG.

The technology is designed to provide a simple, non-invasive approach to cardiovascular assessment without radiation, contrast agents, or invasive procedures. Arslon is developing solutions that can analyze coronary artery stenosis and myocardial ischemia, including ECG-derived fractional flow reserve (eFFR), to support the early identification of patients who may benefit from further cardiac evaluation.

Arslon is currently conducting clinical and technical validation in collaboration with domestic and international medical and research institutions. The company is preparing for regulatory approval and commercialization, with the goal of applying its technology in hospitals, health screening centers, and other healthcare settings following regulatory clearance.

Arslon is also expanding its global network and seeking clinical research, technology, distribution, and business partnerships with healthcare organizations, research institutions, medical technology companies, and other industry partners worldwide.